- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 3
- States / cities
- Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Breast Cancer
- Interventions
- (vic-)trastuzumab duocarmazine, Physician's choice
- Drug
- Lead sponsor
- Byondis B.V.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Tucson, Arizona • San Diego, California + 17 more
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more
- Conditions
- Breast Cancer
- Interventions
- Ipatasertib, Placebo, Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Fulvestrant, BKM120, BKM120 matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more
- Conditions
- ER+ and AR+ Breast Cancer
- Interventions
- GTx-024
- Drug
- Lead sponsor
- GTx
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Fort Lauderdale, Florida • Boston, Massachusetts • Billings, Montana + 1 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Pegylated Liposomal Doxorubicin Hydrochloride, Tamoxifen
- Procedure · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing, Exemestane, Fludeoxyglucose F-18, Fluorine F 18 Fluoro Furanyl Norprogesterone, Fulvestrant, Gonadotropin-releasing Hormone Analog, Letrozole, Positron Emission Tomography, Tamoxifen, Therapeutic Estradiol
- Drug · Procedure · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Seattle, Washington
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- ETBX-011, ALT-803
- Biological
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Solid Tumor, Adult
- Interventions
- DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 16
- States / cities
- Irvine, California • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, trastuzumab, pertuzumab
- Drug · Biological
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • St Louis, Missouri • New York, New York + 2 more
- Conditions
- Advanced Breast Cancer, Breast Cancer
- Interventions
- Neratinib, Lapatinib, Capecitabine
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Murrieta, California • Orange, California + 40 more
- Conditions
- Solid Cancers, Non-Hodgkin's Lymphoma
- Interventions
- Fulvestrant, GDC-0032, Letrozole, Midazolam
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- Eribulin, Cyclophosphamide, Docetaxel
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 15
- States / cities
- Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 12 more
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, cyclophosphamide, docetaxel, doxorubicin hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 5
- States / cities
- Cleveland, Ohio • Middleburg Heights, Ohio • Orange, Ohio + 2 more
- Conditions
- Breast Cancer
- Interventions
- E7389
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 48 more
- Conditions
- Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
- Interventions
- [68Ga]Ga-ABY-025
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Cancer
- Interventions
- PF-07248144, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 102
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
- Conditions
- Breast Cancer
- Interventions
- capecitabine (Xeloda®), docetaxel (Taxotere®)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 39 more
- Conditions
- Breast Cancer
- Interventions
- cisplatin, everolimus, paclitaxel, placebo, Venous blood draw
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Jackson, Mississippi • Hershey, Pennsylvania + 3 more
- Conditions
- Locally Advanced Malignant Neoplasm, Breast Cancer
- Interventions
- Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
- Drug · Other · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Interventions
- ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride
- Drug · Procedure
- Lead sponsor
- Laura Huppert, MD, BA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 13
- States / cities
- Fort Myers, Florida • Jacksonville, Florida • Lakeland, Florida + 10 more
- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 650
- Drug
- Lead sponsor
- Volastra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Santa Monica, California • Indianapolis, Indiana + 10 more